Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
Clinicians have an important role in helping donation centers make the most of exciting advances and meet recent challenges.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Approval was based on data from the AGAVE-201 trial and is for use in adult and pediatric patients who weigh at least 40 kg.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
In a study SCT appeared linked to an increased risk of pregnancy-associated VTE, pulmonary embolism, and isolated DVT.
Advertisement
Conference Coverage
Major highlights with a focus on MDS from the 66th American Society of Hematology Annual Meeting & Exposition
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Expert Interviews on Hematology
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.